News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Bone and joint problems news

Show

From To
PrEP science
Truvada as PrEP Tied to Only Modest Bone Density Decline

A new analysis also found a correlation between higher adherence to the daily drug regimen and greater bone density loss.

Published
17 June 2019
From
POZ
Bone and joint problems
Aging HIV population face complicated rheumatologic care

As the national population of patients who are HIV-positive continues to age, rheumatologists will be increasingly called on to manage routine care for crystal disease, osteoarthritis, soft tissue rheumatism and other conditions, according to Leonard Calabrese, DO, of the Cleveland Clinic.

Published
22 May 2019
From
Healio
Bone and joint problems
US study suggests that ageing people with HIV may have an increased risk of arthritis

HIV infection and antiretroviral therapy are associated with increased risk of cartilage damage in the knee associated with osteoarthritis, according to the results of a small US study

Published
16 May 2019
By
Michael Carter
PrEP science
Descovy is non-inferior to Truvada for daily PrEP

A daily pill containing the newer formulation of tenofovir in combination with emtricitabine (Descovy) had a comparable protective effect to the existing daily pill which contains the older

Published
06 March 2019
By
Roger Pebody
Bone and joint problems
Use of Testosterone in Men With HIV Is Associated With Higher Bone Mineral Density

Men with HIV who use testosterone have greater bone mass density (BMD) T-scores at the lumbar spine, total hip, and femoral neck compared with nonusers, according to the results of a recent study.

Published
03 January 2019
From
American Journal of Managed Care
Side-effects
Doubt cast on link between tenofovir disoproxil and bone fractures

Treatment with tenofovir disoproxil fumarate (TDF) does not increase the risk of fractures, according to French research published in the online edition of the Journal of Acquired

Published
07 December 2018
By
Michael Carter
PrEP science
How safe is PrEP? Meta-analysis finds no increased risk of serious side-effects

A meta-analysis of randomised controlled trials of tenofovir or tenofovir/emtricitabine as pre-exposure prophylaxis (PrEP) has found no increase in the risk of serious adverse health

Published
02 November 2018
By
Gus Cairns
Bone and joint problems
Zoledronic acid is more effective than switching from tenofovir in HIV-positive people with low bone mineral density

Two infusions of zoledronic acid resulted in significantly greater increases in bone mineral density over 24 months than switching from tenofovir disoproxil fumarate (TDF) in virologically suppressed, HIV-positive

Published
24 September 2018
By
Alain Volny-Anne
Ageing and HIV
Frailty in men with HIV linked with bone weakness, muscle loss and large waist

Frailty is twice as prevalent in middle-aged and elderly HIV-positive men as in their HIV-negative peers, investigators from the Multicenter AIDS Cohort Study (MACS) report

Published
13 June 2018
By
Michael Carter
Treatment outcomes and life expectancy
TAF only superior to TDF when used with a boosting agent

The benefits of tenofovir alafenamide (TAF) over tenofovir disoproxil fumarate (TDF) may have been overstated, according to the results of a meta-analysis published in the

Published
10 April 2018
By
Michael Carter
← First12345...13Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.